SCHEMBL7048015

SCHEMBL7048015

CCOC(=O)C(CC1CCCCC1)CP(=O)(COS(=O)(=O)c1ccc(C)cc1)OCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
TP53 P04637 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ENPP3 O14638 2/20 0.35
ENPP1 P22413 2/20 0.35
ENPP2 Q13822 2/20 0.35
ADORA3 P0DMS8 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PLAU P00749 1/20 0.35
HPN P05981 1/20 0.35
GAA P10253 1/20 0.34
KCNH2 Q12809 1/20 0.34
KMT2A Q03164 1/20 0.34
POLB P06746 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7051748 0.84 MMP1 (0.33) KMT2AATM
SCHEMBL7050321 0.83 CA2 (0.39) ALDH1A1HSD17B10GAAKMT2APOLB
SCHEMBL7052659 0.83 HSD17B10 (0.41) ALDH1A1TP53L3MBTL1TSHRHSD17B10
SCHEMBL7050902 0.81 PPARG (0.42) HSD17B10GAAPOLBLMNA
SCHEMBL7052394 0.78 ALDH1A1 (0.39) ALDH1A1HSD17B10PLAUHPNPOLB
SCHEMBL9242478 0.78 MMP1 (0.38) ALDH1A1NPSR1TSHRKMT2AATM
SCHEMBL7049015 0.77 MMP1 (0.37) ALDH1A1NPSR1TSHRKMT2AATM
SCHEMBL7051776 0.77 FKBP1A (0.40) ALDH1A1POLBLMNA
SCHEMBL9246196 0.76 MMP1 (0.36) ALDH1A1KMT2A
SCHEMBL7049610 0.74 ALDH1A1 (0.39) ALDH1A1NPSR1L3MBTL1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 ALDH1A1 465/4885TP53 2896/4885ALOX15 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.